Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response

Psychiatry Research

Volumn 230, Issue 3, 2015, Pages 846-852

  Lin, Kathleen Watson ^a   Wroolie, Tonita E ^a   Robakis, Thalia ^a   Rasgon, Natalie L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant response; Clinical trial; Depressive disorders; Insulin resistance; PPAR agonist; Treatment resistant

Indexed keywords

PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGE; BLOOD; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADJUVANTS, PHARMACEUTIC; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84947336686     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.10.013     Document Type: Article

References (39)

1. Boyd F.T., Clarke D.W., Muther T.F., Raizada M.K. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J. Biol. Chem. 1985, 260:15880-15884.
2. Davis S., Colburn C., Dobbins R. Evidence that the brain of the conscious dog is insulin sensitive. J. Clin. Investig. 1995, 95:593-602.
3. Eissa A.A., Al-Rasheed N.M. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 2009, 20:635-642.
4. First M.B., Spitzer R.L., Gibbon M.W.J.B., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 2/2001 revision) 1997, American Psychiatric Press, Inc., Washington, DC.
5. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
6. Gold, P.W., Martinez, P., Haim, A., Eskandari, F., Cizza, G., Alesci, S., Kling, M., Quon, M., 2005. Decreased insulin sensitivity and increased plasma insulin, glucose, and triglyceride concentrations and their interactions in remitted patients with major depression: evidence for an incipient metabolic syndrome. Society of Biological Psychiatry 60th Annual Scientific Convention and Meeting. Atlanta, GA.
7. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Jacober S.J. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
8. Goodnick P. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry 2001, 13(1):31-41.
9. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
10. Heninger G., Mueller P., Davis L. Depressive symptoms and the glucose tolerance test and insulin tolerance test. J. Nerv. Ment. Dis. 1975, 161:421-432.
11. Kashani L., Omidvar T., Farazmand B., Modabbernia A., Ramzanzadeh F., Tehraninejad E.S., Akhondzadeh S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 2013, 38:767-776.
12. Kemp D.E., Ismail-Beigi F., Ganocy S.J., Conroy C., Gao K., Obral S., Calabrese J.R. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Disord. 2012, 136:1164-1173.
13. Kemp D.E., Schinagle M., Gao K., Conroy C., Ganocy S.J., Ismail-Beigi F., Calabrese J.R. PPAR - gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs 2014, 28:571-581.
14. Kenna H., Rasgon N. Insulin resistance link between depressive disorders and cognitive dysfunction. Metabolic Syndrome and Neuropsychiatric Disorders 2008, Informa, New York. J. Stubenrauch (Ed.).
15. Kerr D., Stanley J.C., Barron M., Thomas R., Leatherdale B.A., Pickard J. Symmetry of cerebral blood flow and cognitive responses to hypoglycemia in humans. Diabetologia 1993, 36(33):73-78.
16. Kovacs P., Hajnal A. In vivo electrophysiological effects of insulin in the rat brain. Neuropeptides 2009, 43:283-293.
17. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22(4):370-379.
18. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J. Am. Med. Assoc. 2007, 298:1180-1188.
19. Lozovsky D., Saller C.F., Kopin I.J. Dopamine receptor binding is increased in diabetic rats. Science 1981, 214:1031-1033.
20. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
21. Mueller P.S., Heninger G.R., McDonald R.K. Intravenous glucose tolerance test in depression. Arch. Gen. Psychiatry 1969, 21:470-477.
22. Nathan R.S., Sachar E.J., Asnis G.M., Halbreich U., Halpern F.S. Relative insulin insensitivity and cortisol secretion in depressed patients. Psychiatry Res. 1981, 4(3):291-300.
23. Okamura F., Tashiro A., Utumi A., Imai T., Suchi T., Tamura D., Sato Y., Suzuki S., Hongo M. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000, 49(10):1255-1260. (Psychiatry Res. 132, 141-147).
24. Okamura F., Tashiro A., Utumi A., Imai T., Suchi T., Tamura D., Hongo M. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metab.: Clin. Exp. 2000, 49:1255-1260.
25. Pandya N., DiGenio A., Gao L., Patel M. Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes. Drugs Aging 2013, 30:429-438.
26. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27(1):24-31.
27. Rasgon N.L., Kenna H.A., Williams K.E., Powers B., Wroolie T., Schatzberg A.F. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci. World J. 2010, 10:321-328.
28. Rasgon N.L., Kenna H.A., Reynolds-May M.F., Stemmle P.G., Vemuri M., Marsh W., Ketter T.A. Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus. Bipolar Disord. 2010, 12(5):504-513.
29. Rasgon, N.L., Altshuler, L.L., Elman, S., Frye, M.A., Gitlin, M., 2002. Increased insulin resistance in women with bipolar disorder. The One Hundred and Fifty-Fifth Annual Meeting of the American Psychiatric Association. American Psychiatric Association, Philadelphia, PA.
30. Sepanjnia K., Modabbernia A., Ashrafi M., Modabbernia M.J., Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double- blind placebo-controlled trial. Neuropsychopharmacology 2012, 37:2093-2100.
31. Shahsavarian A., Javadi S., Jahanabadi S., Khoshnoodi M., Shamsaee J., Shafaroodi H., Dehpour A. Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR - gamma receptor and nitric oxide pathway. Eur. J. Pharmacol. 2014, 745:52-58.
32. Sluzewska A., Sobieska M., Rybakowski J.K., Rybakowski J.K. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997, 35:123-127.
33. Stemmle P.G., Kenna H.A., Wang P.W., Hill S.J., Ketter T.A., Rasgon N.L. Insulin resistance and hyperlipidemia in women with bipolar disorder. J. Psychiatr. Res. 2009, 43(3):341-343.
34. Stewart J.C., Rand K.L., Muldoon M.F., Kamarck T.W. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav. Immun. 2009, 23:936-944.
35. Thase M.E., Entsuah R., Cantillon M., Kornstein S.G. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J. Women's Health 2005, 14:609-616.
36. Yip J., Facchini F.S., Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. 1998, 83:2773-2776.
37. Zanardi R., Cusin C., Rossini D., De Ronchi D., Serretti A. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. J. Clin. Psychopharmacol. 2003, 23:535-539.
38. Zeinoddini A., Sorayani M., Hassanzadeh E., Arbabi M., Farokhnia M., Salimi S., Akhondzadeh S. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depression Anxiety 2015, 32:167-173.
39. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 2001, 15(3):199-226.